<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499716</url>
  </required_header>
  <id_info>
    <org_study_id>2020/04</org_study_id>
    <nct_id>NCT04499716</nct_id>
  </id_info>
  <brief_title>Quadriblock Versus &quot;IPACK + Femoral Triangle Block + Obturator Nerve Block&quot; in Total Knee Arthroplasty</brief_title>
  <acronym>QuITO</acronym>
  <official_title>Quadriblock Versus &quot;IPACK + Femoral Triangle Block + Obturator Nerve Block&quot; in Total Knee Arthroplasty: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Medipole Garonne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Medipole Garonne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty (TKA) is one of the most common orthopedic surgical procedure and is&#xD;
      associated with severe pain in the immediate postoperative period, thus limiting early&#xD;
      recovery.&#xD;
&#xD;
      Postoperative pain management requires multimodal analgesia, combining drugs and injection of&#xD;
      a local anesthetic (LA). For optimal pain management, several peripheral nerve blocks should&#xD;
      be associated. Thus, a recent study shows that the combination of IPACK, femoral triangle and&#xD;
      obturator nerve blocks (ITO blocks) provides an effective pain control after TKA.&#xD;
&#xD;
      The hypothesis of this study is that a quadruple nerve block combining femoral, sciatic,&#xD;
      obturator and lateral femoral cutaneous nerve blocks (quadri-block) could improve analgesia&#xD;
      after TKA.&#xD;
&#xD;
      The main objective of this monocenter, prospective, randomized, open-label, controlled trial&#xD;
      is to assess the effect of quadri-block on morphine consumption after TKA compared to ITO&#xD;
      blocks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the pre-anaesthesia room, after the implementation of classical monitoring with an oxygen&#xD;
      mask and a peripheral venous catheter, all patients will receive an antibioprophylaxis&#xD;
      according to SFAR (French Society of Anesthesia &amp; Intensive Care Medecine) recommendations&#xD;
      and injection of 10 mg of IV dexamethasone.&#xD;
&#xD;
      The patients will be then randomized in 2 groups:&#xD;
&#xD;
        -  ITO group (usual technique): IPACK combined to femoral triangle and obturator nerve&#xD;
           blocks&#xD;
&#xD;
        -  Quadriblock group (experimental technique): femoral, sciatic, obturator and lateral&#xD;
           femoral cutaneous nerve blocks.&#xD;
&#xD;
      An experienced anesthetist will perform ultrasound-guided blocks 30 minutes before surgery&#xD;
      with ropivacaine 0.3%, total volume of 70 ml.&#xD;
&#xD;
      In the operating room, general anesthesia will be induced by intravenous ketamine (0.4 mg/kg)&#xD;
      and propofol (3 mg/kg). Anesthesia will be maintained with propofol.&#xD;
&#xD;
      Postoperative analgesia protocol :&#xD;
&#xD;
        -  Multimodal analgesia will be instituted from the end of the surgery by the&#xD;
           administration of paracetamol (1 g) and ketoprofen (100 mg).&#xD;
&#xD;
        -  In post-anesthesia care unit (PACU): oxynorm titration if VRS (pain score) &gt;3 according&#xD;
           to the centre's usual care.&#xD;
&#xD;
        -  In ward: systematic per os analgesia with paracetamol (1 g, 4 times a day) and ibuprofen&#xD;
           (400 mg, 3 times a day); oxynorm (10 mg, lockout interval: 4 h) if VRS (pain score) &gt;3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">May 7, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesia, defined by the morphine consumption in the first 48 hours post-surgery.</measure>
    <time_frame>48 hours</time_frame>
    <description>Total amount of oxynorm (mg) administered during the first 48 hours post-surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain: Verbal Rating Scale (VRS)</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain will be assessed every 6 hours using a Verbal Rating Scale (VRS) ranging from 0 to 10 (0=no pain, 10=worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxynorm consumption in the first 24 hours post-surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Total amount of oxynorm (mg) administered during the first 24 hours post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to walk</measure>
    <time_frame>48 hours</time_frame>
    <description>0: unable to get up; 1: able to get up but not to walk; 2: walk &lt;50 m; 3: walk &gt; 50 m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quadricep mobilization</measure>
    <time_frame>48 hours</time_frame>
    <description>0: paralysis; 1: paresis, 2: normal contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foot elevator muscle mobilization</measure>
    <time_frame>48 hours</time_frame>
    <description>0: paralysis; 1: paresis; 2: normal contraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of opioids</measure>
    <time_frame>48 hours</time_frame>
    <description>Collect side effects associated with oxynorm : nausea or vomiting, drowsiness, constipation, urinary retention, itching, disorientation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Primary Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Arm 1: ITO group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: IPACK combined with femoral triangle and obturator nerve blocks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 : Quadri-block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 : Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPACK</intervention_name>
    <description>25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.</description>
    <arm_group_label>Arm 1: ITO group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femoral triangle block</intervention_name>
    <description>25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.</description>
    <arm_group_label>Arm 1: ITO group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Obturator nerve block</intervention_name>
    <description>20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.</description>
    <arm_group_label>Arm 1: ITO group</arm_group_label>
    <arm_group_label>Arm 2 : Quadri-block group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femoral nerve block</intervention_name>
    <description>20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.</description>
    <arm_group_label>Arm 2 : Quadri-block group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sciatic nerve block</intervention_name>
    <description>25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.</description>
    <arm_group_label>Arm 2 : Quadri-block group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lateral femoral cutaneous nerve block</intervention_name>
    <description>5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.</description>
    <arm_group_label>Arm 2 : Quadri-block group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older,&#xD;
&#xD;
          -  Primary total knee arthroplasty&#xD;
&#xD;
          -  Consent for participation,&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative morphine use&#xD;
&#xD;
          -  Chronic pain syndrome&#xD;
&#xD;
          -  Contraindication to any drugs used in the protocol (paracetamol, ketoprofen, oxynorm,&#xD;
             propofol, ketamine, ropivacaine)&#xD;
&#xD;
          -  Valgus &gt; 9°&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients under protection of the adults (guardianship, curators or safeguard of&#xD;
             justice)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique Médipôle Garonne</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee arthroplasty, Regional anesthesia, Ropivacaine, Postoperative analgesia, Pain management, Opioids</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

